Waiting for platelet counts causes unsubstantiated delay of thrombolysis therapy

European Neurology

Volumn 69, Issue , 2013, Pages 317-320

  Breuer, L ^a   Huttner, H B ^a   Kiphuth, I C ^a   Ringwald, J ^a   Hilz, M J ^a   Schwab, S ^a   Kohrmann M ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Platelet count; Stroke; Thrombocytopenia; Thrombolysis

Indexed keywords

FIBRINOLYTIC AGENT;

ADULT; AGED; ARTICLE; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; THERAPY DELAY; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

EID: 84875665785     PISSN: 00143022     EISSN: 14219913     Source Type: Journal    
DOI: 10.1159/000345702     Document Type: Article

References (13)

1. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995; 333: 1581-1587.
2. Hacke W, Kaste M, Bluhmki E, et al: Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008; 359: 1317-1329.
3. European Stroke Organisation (ESO) Executive Committee, ESO Writing Committee: Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis 2008; 25: 457-507.
4. Adams HP Jr, del Zoppo G, Alberts MJ, et al: Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke 2007; 38: 1655-1711.
5. Cucchiara BL, Jackson B, Weiner M, Messe SR: Usefulness of checking platelet count before thrombolysis in acute ischemic stroke. Stroke 2007; 38: 1639-1640.
6. Meretoja A, Putaala J, Tatlisumak T, et al: Off-label thrombolysis is not associated with poor outcome in patients with stroke. Stroke 2010; 41: 1450-1458.
7. Rost NS, Masrur S, Pervez MA, Viswanathan A, Schwamm LH: Unsuspected coagulopathy rarely prevents IV thrombolysis in acute ischemic stroke. Neurology 2009; 73: 1957-1962.
8. Lees KR, Bluhmki E, von Kummer R, et al: Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet 2010; 375: 1695-1703.
9. Tanne D, Kasner SE, Demchuk AM, et al: Markers of increased risk of intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke in clinical practice: the Multicenter rt-PA Stroke Survey. Circulation 2002; 105: 1679-1685.
10. Kohrmann M, Schellinger PD, Breuer L, et al: Avoiding in hospital delays and eliminating the three-hour effect in thrombolysis for stroke. Int J Stroke 2011; 6: 493-497.
11. Slichter SJ: Relationship between platelet count and bleeding risk in thrombocytopenic patients. Transfus Med Rev 2004; 18: 153-167.
12. Aledort LM, Hayward CP, Chen MG, Nichol JL, Bussel J: Prospective screening of 205 patients with ITP, including diagnosis, serological markers, and the relationship between platelet counts, endogenous thrombopoietin, and circulating antithrombopoietin antibodies. Am J Hematol 2004; 76: 205-213.
13. Lee YJ, Jy W, Horstman LL, et al: Elevated platelet microparticles in transient ischemic attacks, lacunar infarcts, and multiinfarct dementias. Thromb Res 1993; 72: 295-304.